<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905968</url>
  </required_header>
  <id_info>
    <org_study_id>TTPLAR</org_study_id>
    <nct_id>NCT02905968</nct_id>
  </id_info>
  <brief_title>Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer</brief_title>
  <official_title>The Safety and Effect of Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer to Prevent Anastomotic Leak: Randomized Control Trial Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of transanual tube placement in
      low anterior resection (LAR) for rectal cancer in preventing anastomotic leakage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anastomotic leak rate</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>Anastomotic leak is a common and serious complication after low anterior, resection, and often leads to re-operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Frame: Reoperation rate after anastomotic leak</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>Anastomotic leak is a common and serious complication after low anterior, resection, and often leads to excrement peritonitis, and re-operation as colostomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>TTPLAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transanual tube placement after anastomosis in low anterior resection for rectal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NORLAR</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Tranditional low anterior resection without transanual tube placement or ileostomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transanual tube placement</intervention_name>
    <description>Transanual tube placement after anastomosis in low anterior resection for rectal cancer.</description>
    <arm_group_label>TTPLAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 75 years;

          2. Primary tumor has undergone histologically confirmed rectal adenocarcinoma; Low rectal
             cancer was defined by the presence of the inferior pole of the tumor below the
             peritoneal reflection (in 11 cm from the anal margin).

          3. Together with clinical or radiological evidence of Stage II (T3-4, N0, M0) or Stage
             III (T1-4, N1-2, M0) disease (according to the 2010 revision of the International
             Union Against Cancer primary tumor, regional nodes, metastasis (TNM) staging system).

          4. Performance status (ECOG) 0~1

          5. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l;
             hemoglobin (Hb) ≥9g/dl (within 1 week prior to randomization)

          6. Adequate hepatic and renal function: Serum bilirubin≤1.5 x upper limit of normal
             (ULN), alkaline phosphatase ≤5x ULN, and serum transaminase (either primary tumor,
             regional nodes, metastasis (AST) or ALT) ≤ 5 x ULN(within 1 week prior to
             randomization);

          7. Written informed consent for participation in the trial.

        Exclusion Criteria:

          1. Body mass index (BMI) more than 30 kg/m2.

          2. Serious pre-operative comorbidity, including cardiovascular disease (coronary
             arteriosclerosis, arrhythmia, heart failure), pulmonary dysfunction (lung emphysema,
             obstructive lung disease), liver insufficiency (Child-Pugh B or C), renal
             insufficiency (serum creatinine &gt;2.0 mg/dl), and arterial circulation disturbance
             (occlusion of arterial vessels of limb in patient's history.

          3. History of accepting abdominal surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuo Yi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianmin Xu, MD</last_name>
    <phone>008613501984869</phone>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General Surgery, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianmin xu, MD</last_name>
      <phone>008613501984869</phone>
      <email>xujmin@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Anastomotic leak</keyword>
  <keyword>Low rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Anastomotic Leak</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

